Last reviewed · How we verify
Relapsing remitting multiple sclerosis
Approved treatments
- Nerventra · Teva
Nerventra works by modulating the immune system to reduce inflammation in the central nervous system. - Zeposia · Bristol-Myers Squibb
Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression. - Aubagio · Sanofi
Teriflunomide inhibits dihydroorotate dehydrogenase, reducing activated lymphocytes in the CNS. - Plegridy · Biogen Idec Inc
Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis. - Mayzent · Novartis Pharmaceuticals
- Campath · National Heart, Lung, and Blood Institute (NHLBI)
- Betaseron · Bayer Healthcare Pharms
Betaseron works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis. - Novantrone
Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division. - Gilenya · Novartis
Gilenya works by binding to and blocking the S1P1 receptor, preventing immune cells from leaving the lymph nodes and reducing inflammation in the central nervous system. - Avonex · Biogen
Avonex works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis. - Tecfidera · Biogen
Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system. - Mayzent · Novartis
Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression. - Campath · Sanofi
Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction. - Zenapax · Hoffman-La Roche
- Leustatin
Leustatin works by inhibiting the enzyme that breaks down cyclic adenosine monophosphate (cAMP), leading to an accumulation of cAMP and subsequent activation of various cellular pathways. - Avonex · Biogen
- Gilenya · University of Southern California
- Plegridy · Holy Name Medical Center, Inc.
- Betaseron · University of Medicine and Dentistry of New Jersey
- Tecfidera · EMD Serono Research & Development Institute, Inc.
- Zenapax · National Institute of Neurological Disorders and Stroke (NINDS)
- Mitozantrone · US Department of Veterans Affairs
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsing remitting multiple sclerosis patent landscape — cliff calendar, originator estates, attackable patents
- Relapsing remitting multiple sclerosis treatment landscape brief
- Relapsing remitting multiple sclerosis treatment updates RSS
Frequently asked questions about Relapsing remitting multiple sclerosis
What drugs treat Relapsing remitting multiple sclerosis?
Tracked treatments include Nerventra, Zeposia, Aubagio, Plegridy, Mayzent, Campath, Betaseron, Novantrone.
What is the treatment for Relapsing remitting multiple sclerosis?
Standard treatment for Relapsing remitting multiple sclerosis includes Nerventra, Zeposia, Aubagio, Plegridy, Mayzent. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Relapsing remitting multiple sclerosis patent cliff · Relapsing remitting multiple sclerosis CI report
- Treatment: Nerventra · Teva
- Treatment: Zeposia · Bristol-Myers Squibb
- Treatment: Aubagio · Sanofi
- Treatment: Plegridy · Biogen Idec Inc
- Treatment: Mayzent · Novartis Pharmaceuticals
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing